Furong Jiao
About Us
Learn more about who we are and how we help advance your programs further and faster.
Services
Browse our full directory of drug discovery services and preclinical testing capabilities.
Find What You Need
Booth #14
The 16th European ISSX European Meeting 2026, held in Basel, Switzerland (June 29–July 2, 2026), will highlight the theme "From Benchside Research to Bedside Reality: DMPK's Next Chapter." This meeting offers a unique platform to connect with leading experts, share cutting-edge research, and gain new perspectives on advancing DMPK from discovery to clinical application.
Sydney Room
Furong Jiao
Abstract: This presentation aims to share key considerations for DMPK strategies during the preclinical development of brain-targeted therapeutics. Key takeaways will include:
Sydney Room
Jie Wang
Abstract: Accurate in vitro plasma protein binding (PPB) assessment is crucial for predicting the distribution, safety, and efficacy of oligonucleotide therapeutics. However, the literature reveals striking discrepancies in siRNA PPB data, largely driven by the choice of assay methodology. This presentation explores the fundamental differences and methodological artifacts between the two predominantly used formats: Ultrafiltration (UF) and Electrophoretic Mobility Shift Assay (EMSA). We will delve into strategies to overcome severe non-specific binding (NSB) in UF and expose the dynamic, condition-dependent artifacts inherent in EMSA. By systematically unraveling these discrepancies, we provide a robust, optimized methodological framework for reliable, regulatory-compliant PPB evaluations, ultimately guiding more accurate ADME profiling in oligonucleotide drug development.
Share your development goals and key challenges with our experts to define the right path forward.